USE OF IMMUNOGENIC COMPOSITIONS FOR THE TREATMENT OR PREVENTION OF PATHOGEN INFECTIONS
The invention provides compositions featuring cationic liposome nucleic acid molecules complexed with pathogen derived antigen and methods of using such compositions for the treatment or prevention of an infectious disease. Other features and advantages of the invention will be apparent from the detailed description, and from the claims.
1 . A vaccine comprising a liposome, a non-coding nucleic acid molecule, and a bacterial, fungal, or parasitic antigen in a pharmaceutically acceptable excipient, wherein the vaccine induces a protective immune response in a vaccinated mammal.
2 . The vaccine of claim 1 , wherein the bacterial, fungal, or parasitic antigen is provided in a membrane fraction.
3 . The vaccine of claim 1 , wherein the liposome is a cationic liposome.
4 . The vaccine of claim 1 , wherein the vaccine prevents or treats a bacterial, fungal, or parasitic infection of the mammal.
5 . The vaccine of claim 1 , wherein the bacteria is a gram positive or gram negative bacteria.
6 . The vaccine of claim 1 , wherein the bacteria is selected from the group consisting of Francisella tularensis, Burkholderia pseudomallei , and Yersinia pestis.
7 . The vaccine of claim 1 , wherein the virus is Influenza virus.
8 . The vaccine of claim 1 , wherein the antigen and the nucleic acid molecule are complexed to or within said liposome.
9 . A vaccine for inducing an F. tularensis specific immune response in a subject, the vaccine comprising a complex comprising an effective amount of a cationic liposome, a non-coding nucleic acid molecule, and a F. tularensis membrane fraction in a pharmaceutically acceptable excipient.
10 . The vaccine of claim 1 , wherein the cationic liposome is octadecenolyoxy[ethyl-2-heptadecenyl-3 hydroxyethyl]imidazolinium chloride.
11 . A method of immunizing a mammal comprising administering to said mammal a vaccine comprising an effective amount of a liposome, a non-coding nucleic acid molecule, and a bacterial antigen in a pharmaceutically acceptable excipient.
12 . A method of treating or preventing a pathogen infection in a mammal in need thereof comprising administering to the mammal an effective amount of a composition comprising a liposome, a non-coding DNA, and a bacterial antigen in a pharmaceutically acceptable excipient,
or
a method of preventing a pathogen infection in an infected subject, the method comprising administering an effective amount of a composition comprising a cationic liposome, a non-coding nucleic acid molecule, and a pathogen antigen.
13 - 17 . (canceled)
18 . A method for inducing an F. tularensis specific immune response, the method comprising administering to a mammal an effective amount of a composition comprising cationic liposome, a non-coding nucleic acid molecule, and a F. tularensis membrane fraction in a pharmaceutically acceptable excipient.
19 . The method of claim 1 , wherein the composition is administered intraperitoneally (IP), subcutaneously (SC), intravenously (IV) or intranasally.
20 . The method of claim 1 , wherein the composition induced production of proinflammatory cytokines from antigen presenting cells.
21 . The method of claim 1 , wherein the composition reduces intracellular pathogen replication.
22 . The method of claim 1 , wherein the composition increases survival of the mammal following pathogen exposure compared to an untreated control mammal.
23 . The method of claim 10 , wherein the composition generates pathogen specific IgM in the mammal.
24 . The method of claim 10 , wherein the method prevents or treats a pathogen infection in the mammal.
25 . The method of claim 24 , wherein the pathogen infection is an infectious disease selected from the group consisting of bacterial meningitis, tularemia, influenza, plague, mellidosis, and pneumonicoccal mediated disease.
26 . The method of claim 10 , wherein the method inhibits intracellular growth of a pathogen.
27 - 32 . (canceled)
33 . A kit for preventing or treating a pathogen infection, the kit comprising an effective amount of a cationic liposome, a non-coding nucleic acid molecule, and a pathogen antigen.
34 - 36 . (canceled)